The Weight Loss Drugs Reshaping Global Medicine Are Now in the Philippines. Who Can Actually Access Them?

What GLP-1 Drugs Actually Do

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone the body naturally produces after eating. They slow gastric emptying, suppress appetite signals in the brain, and stimulate insulin secretion in response to rising blood sugar. The result is a reduction in both blood glucose and body weight, which is why the same class of drugs is approved for two distinct indications: type 2 diabetes management and chronic weight loss.

The most widely known GLP-1 drug is semaglutide, sold as Ozempic for diabetes and at a higher dose as Wegovy for weight management, both manufactured by Denmark-based Novo Nordisk. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity in other markets, is a dual agonist that also targets the GIP receptor and has shown stronger weight loss results than semaglutide in head-to-head clinical trials. Clinical trial data show that semaglutide produces weight loss of up to 15 percent of body weight in people with obesity, while tirzepatide has achieved 20 percent or more at higher doses.

Why the Philippines Has a Real Need for These Drugs

The epidemiological case for GLP-1 drugs in the Philippines is compelling. The 2025 updating survey of the Food and Nutrition Research Institute found that 44.5 percent of Filipino adults aged 20 to 59 are classified as obese, up from 39.8 percent in 2023. That is a five percentage point jump in just two years. Obesity prevalence was highest in the National Capital Region at 52.7 percent, and significantly higher among women, urban residents, and higher-income households.

The diabetes burden is equally significant. An estimated 4.3 million Filipinos were living with diagnosed diabetes in 2021, with an additional 2.8 million estimated to be undiagnosed. Diabetes prevalence is projected to reach 7.5 million by 2045. Diabetic nephropathy already accounts for 38 percent of renal disease cases in the country. Both obesity and type 2 diabetes sit squarely within the approved indications for GLP-1 therapy.

What Is Available in the Philippines and What It Costs

Ozempic, the semaglutide formulation approved for type 2 diabetes, received FDA Philippines registration in 2022. Wegovy, the higher-dose version for chronic weight management, entered the Philippine market in late 2025 following Novo Nordisk Philippines securing local regulatory approval. Tirzepatide is available in select tertiary hospital pharmacies and specialty clinics. All three are prescription-only medications.

Ozempic retails at approximately 7,560 pesos per injection pen at licensed pharmacies including Mercury Drug and Watsons. Each pen provides four weekly doses, meaning the monthly cost for Ozempic at the starting dose is roughly that amount, rising as doses increase. Wegovy, given its higher semaglutide concentration, is generally priced at approximately double the cost of Ozempic. Tirzepatide runs between 12,000 and 20,000 pesos per month at maintenance doses in clinics carrying it.

PhilHealth does not cover GLP-1 drugs for weight management. HMO coverage for the diabetes indication is available in some plans but typically requires pre-authorization and documented HbA1c levels above the diagnostic threshold. For the vast majority of Filipino patients, these are fully out-of-pocket expenses.

Supply Constraints and the Counterfeit Risk

Global demand for semaglutide has consistently outpaced supply since 2022, when off-label prescribing for weight loss began driving shortages that affected even diabetes patients who needed Ozempic for its approved purpose. The World Health Organization raised an alert over falsified semaglutide products circulating internationally, including in the Philippines, as early as 2022. FDA Philippines echoed that warning and attributed the supply disruption directly to the unexpected surge in demand from off-label weight loss use.

The counterfeit risk in the Philippines is real and documented. Both Ozempic and Wegovy require strict cold-chain storage between two and eight degrees Celsius to maintain effectiveness. Products sold through social media, online marketplaces, or informal networks frequently lack proper refrigeration and cannot be verified as genuine. In June 2024, WHO issued a formal Medical Product Alert on falsified Ozempic batches, noting that its Global Surveillance and Monitoring System had been tracking increased reports of falsified semaglutide products across all geographic regions since 2022, including the Philippines. Novo Nordisk Philippines has advised the public to purchase only from licensed pharmacies with valid prescriptions, noting that broken cold-chain handling alone renders a pen ineffective regardless of whether it contains the genuine drug.

• Only purchase from FDA-registered pharmacies with a valid prescription from a licensed physician
• Verify the pen includes a visible batch number and expiry date
• Avoid purchases through Lazada, Shopee, social media sellers, or informal group-buy arrangements
• Report suspicious products or stockouts to FDA Philippines through official channels

What the Clinical Evidence Says About Long-Term Use

GLP-1 drugs are not short-term interventions. Clinical data from the STEP 4 trial on semaglutide showed that most patients regain a significant portion of lost weight within 12 months of stopping the medication, because the biological drivers of excess weight resume once the drug clears. This positions these medications as chronic treatments rather than courses, which has direct implications for the total cost burden on Filipino patients and any future coverage decisions by PhilHealth or private insurers.

The cardiovascular data is a separate and important signal. Large trials have demonstrated that semaglutide reduces major cardiovascular events in patients with existing heart disease, an outcome that goes beyond weight and glucose control and strengthens the case for broader access from a public health perspective. A 2026 review in a peer-reviewed journal confirmed receptor occupancy rates above 90 percent for long-acting agents, correlating with sustained effects throughout a 24-hour dosing window.